The potential role of interleukins and interferons in ovarian cancer

Huldani Huldani; Sana Abdul-Jabbar Ali; F Al-Dolaimy; Ahmed Hjazi; Nikolenko Denis Andreevich; Khulood H Oudaha; Abbas F Almulla; Ali Alsaalamy; Shamam Kareem Oudah; Yasser Fakri Mustafa

doi:10.1016/j.cyto.2023.156379

The potential role of interleukins and interferons in ovarian cancer

Cytokine. 2023 Nov:171:156379. doi: 10.1016/j.cyto.2023.156379. Epub 2023 Sep 26.

Authors

Affiliations

¹ Department of Physiology, Faculty of Medicine, Lambung Mangkurat University, Banjarmasin, South Kalimantan, Indonesia.
² Pharmacy Department, AlSafwa University College, Karbalaa, Iraq. Electronic address: sana.a.ali@alsafwa.edu.iq.
³ Al-Zahraa University for Women, Karbala, Iraq.
⁴ Department of Medical Laboratory Sciences, College of Applied Medical Sciences, Prince Sattam bin Abdulaziz University, Al-Kharj 11942, Saudi Arabia.
⁵ Sechenov First Moscow State Medical University, Russia.
⁶ Pharmaceutical Chemistry Department, College of Pharmacy, Al-Ayen University, Thi-Qar, Iraq.
⁷ College of Technical Engineering, the Islamic University, Najaf, Iraq; College of Technical Engineering, the Islamic University of Al Diwaniyah, Iraq; College of Technical Engineering, the Islamic University of Babylon, Iraq.
⁸ College of Technical Engineering, Imam Ja'afar Al-Sadiq University, Al-Muthanna 66002, Iraq.
⁹ College of Pharmacy, National University of Science and Technology, Dhi Qar, Iraq.
¹⁰ Department of Pharmaceutical Chemistry, College of Pharmacy, University of Mosul, Mosul 41001, Iraq.

PMID: 37757536
DOI: 10.1016/j.cyto.2023.156379

Abstract

Ovarian cancer poses significant challenges and remains a highly lethal disease with limited treatment options. In the context of ovarian cancer, interleukins (ILs) and interferons (IFNs), important cytokines that play crucial roles in regulating the immune system, have emerged as significant factors influencing its development. This article provides a comprehensive review of the involvement of various ILs, including those from the IL-1 family, IL-2 family, IL-6 family, IL-8 family, IL-10 family, and IL-17 family, in ovarian cancer. The focus is on their impact on tumor growth, metastasis, and their role in evading immune responses within the tumor microenvironment. Additionally, the article conducts an in-depth examination of the oncogenic or antitumor roles of each IL in the context of ovarian cancer pathogenesis and progression. Besides, we elucidated the enhancements in the treatment of ovarian cancer through the utilization of type-I IFN and type-II IFN. Recent research has shed light on the intricate mechanisms through which specific ILs and IFNs contribute to the advancement of the disease. By incorporating recent findings, this review also seeks to inspire further investigations into unexplored mechanisms, fostering ongoing research to develop more effective therapeutic strategies for ovarian cancer. Moreover, through an in-depth analysis of IL- and IFN-associated clinical trials, we have highlighted their promising potential of in the treatment of ovarian cancer. These clinical trials serve to reinforce the significant outlook for utilizing ILs and IFNs as therapeutic agents in combating this disease.

Keywords: Cancer therapy; Cytokines; Interferon; Interleukin; Ovarian carcinoma.

Publication types

Review